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ABSTRACT
Although the medical treatment of colorectal cancer has evolved greatly in the 
last years, a significant portion of early-stage patients develops recurrence after 
therapies. The current clinical trials are directed to evaluate new drug combinations 
and treatment schedules.
By the use of patient-derived or established colon cancer cell lines, we found 
that the tyrosine kinase receptor HER3 is involved in the mechanisms of resistance 
to therapies. In agreement, the immunohistochemical analysis of total and phospho-
HER3 expression in 185 colorectal cancer specimens revealed a significant correlation 
with lower disease-free survival.
Targeting HER3 by the use of the monoclonal antibody patritumab we found 
induction of growth arrest in all cell lines. Despite the high efficiency of patritumab 
in abrogating the HER3-dependent activation of PI3K pathway, the HER2 and EGFR-
dependent MAPK pathway is activated as a compensatory mechanism. Interestingly, 
we found that the MEK-inhibitor trametinib inhibits, as expected, the MAPK pathway 
but induces the HER3-dependent activation of PI3K pathway. The combined treatment 
results in the abrogation of both PI3K and MAPK pathways and in a significant 
reduction of cell proliferation and survival. 
These data suggest a new strategy of therapy for HER3-overexpressing colon 
cancers.
INTRODUCTION
Colorectal cancer (CRC) is the third most frequent 
cancer in males and the second in females. The majority 
of CRC patients have sporadic disease, while genetic 
mutations are estimated to account for only 5% to 6% of 
CRC cases overall [1].
The current treatment for CRC is based on 
combination therapies that in most cases include surgery, 
local radiotherapy and chemotherapy. 5-FluoroUracil 
(5-FU) combined with leucovorin and irinotecan 
(FOLFIRI) is the recommended first-line chemotherapy 
for CRC; Oxaliplatin (Ox) is used in combination 
with leucovorin and 5-FU in the FOLFOX regimen. 
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Nevertheless, the development of drug resistance 
still occurs in a great number of patients determining 
recurrence.
Several current clinical trials are directed to evaluate 
new drug combinations, in order to enhance tumor 
regression, increase overall survival, and improve the 
quality of life for CRC patients.
In this work, we provide evidence of the crucial 
role played by the tyrosine kinase receptor HER3 in the 
development of resistance to 5-FU and Ox treatments in 
CRC cells. HER3 belongs to the ErbB family of tyrosine 
kinase receptors, and its up-regulation as well as its 
activation by over-expression of its ligand, Heregulin-β1 
(HRG-β1), are commonly seen in various malignancies 
[2–5]. In human breast cancers, HER3 overexpression has 
been reported in 50–70% of cases [6–8] and seems to be 
associated with metastasis [8], tumor size, and risk of local 
recurrence [9]. In addition, HER3 protein overexpression 
has been reported to correlate with resistance to tamoxifen 
in hormone-dependent breast cancer [10], and resistance to 
trastuzumab in HER2-overexpressing breast cancer [11]. 
Increased HER3 mRNA or protein is commonly seen 
in colon carcinomas and is associated with lymph node 
metastasis and a shorter time to progression [12–15]. 
Owing to structural features that limit its intrinsic 
kinase activity, HER3 cannot be auto-phosphorylated but can 
be trans-phosphorylated through hetero-dimerization with 
other family members, such as HER2 [16–18]. Heterodimers 
of HER3 with other HER family members signal through 
the PI3K/AKT pathway, which have been implicated in the 
insurgence of chemoresistance of breast, ovarian, colon, 
gastric, and lung cancer cells. In particular, the HER-2/HER-
3 heterodimer is considered an oncogenic unit, being the 
strongest activator in nature of the PI3K/AKT pathway [19]. 
HER3 is a promising onco-therapeutic target [20]. 
Amongst the many HER3 inhibitors developed and 
currently in early clinical development [21], patritumab is 
the first fully humanized monoclonal antibody targeting 
HER3. Patritumab has shown promising anti-tumor effects 
in CRC [22] and breast cancer in-vitro and in-vivo cancer 
models, where it effectively blocked HER3 phosphorylation, 
degraded HER3, and decreased tumor burden [23–24]. 
A phase-I clinical study has deemed patritumab safe for 
patient use and is now being expanded to a phase-II study 
for treatment of various solid tumor types [25].
Tumor heterogeneity influencing signaling 
cascades in human cancer affects tumor progression 
and metastatization [26–27]. The aberrant activation of 
RAS/BRAF pathway commonly occurs through gain-of-
function mutations in genes encoding family members, 
suggesting that this axis is the regulatory hotspot of the 
pathway [28–31].
The frequency of mutations and the upstream 
signals that activate this pathway render ERK molecules 
good targets for new drugs, with the aim to overcome the 
mechanism of drug resistance.
Despite the great number of highly specific and 
highly potent MEK1/2 inhibitors developed and evaluated 
in clinical studies, only the MEK inhibitor trametinib has 
gained FDA approval for clinical use, specifically for the 
treatment of BRAFV600E/K-mutant melanoma [32–33]. 
Most of the others agents exhibited only limited efficacy 
as single-agent therapies and failed to demonstrate 
substantial clinical activity in most tumor types in which 
they have been studied. Such a lack of response to 
inhibition of a pathway that is activated in cancer results 
from activation of compensatory pathways that support 
cancer cell viability in the presence of the inhibitory drug 
[34]. Specifically, HER3 has been involved in intrinsic 
resistance to MEK inhibition [35–36]. 
These observations, together with our findings 
supporting the role played by HER3 in the development 
of resistance to hormone and herceptin therapies [10–11], 
prompted us to test a new drug combination, involving 
the monoclonal antibody patritumab, targeting HER3, 
and the MEK-inhibitor trametinib. Our results suggest 
that this combination protocol could represent a new 
therapeutic approach to escape drug-resistance in HER3-
overexpressing CRC.
RESULTS
HER3 is involved in the mechanisms of 
resistance of colon cancer cells to chemotherapy
In order to evaluate the involvement of HER3 in the 
responsiveness of colon cancer cells to chemotherapies, 
we analyzed three patient-derived colon cancer cell lines 
(Pt-1, Pt-2, Pt-3) and the established colon cancer cell line 
HT29. All cell lines were characterized for the mutations 
of BRAF, KRAS, and PIK3CA oncogenes, for the status of 
p53 (Supplementary Table S1), and for the expression of 
EGFR family members, whose expression and activity has 
been described strictly correlated with the responsiveness 
to therapy (Supplementary Figure S1) [10–11, 37]. 
We found that the depletion of HER3 by specific 
siRNA (siHER3) induces per se cell death in Pt-1 and Pt-2 
patient-derived cell lines, whereas it has no significant 
effect in HT29 colon cancer cells (Figure 1A and 1B, upper 
panels). Interestingly, siHER3 rescues the responsiveness of 
Pt-1 and Pt-2 cells to 5-FU and Ox treatments (p < 0.05 and 
p < 0.001), which are almost ineffective per se. Even though 
the in vitro treatment with 5-FU and Ox alone induces 
down-regulation of HER3, the residual expression of the 
receptor is sufficient to induce drug-resistance (Figure 1A 
and 1B, upper panels). HT29 cells showed a partial 
response only to 5-FU, but not to Ox (Figure 1A and 1B, 
upper panels); nevertheless the depletion of HER3 in 
combination with chemotherapy in HT29 is not as effective 
as in patient-derived cell lines. The combined treatment 
induces significant levels of apoptosis, as indicate by PARP 
cleavage (Figure 1A, lower panels), or by reduction of 
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total PARP (Figure 1B, lower panels). These results were 
further validated by TUNEL assay showing that siHER3 
alone and in combination with 5FU or Ox induces cell 
death by apoptosis (Supplementary Figure  S2A and S2B). 
These data strongly suggest that HER3 and the signaling 
pathways downstream could be involved in the mechanisms 
of resistance to chemotherapy in colon cancer cells. In 
agreement with this hypothesis, we found a strong down-
regulation of PI3K/AKT signaling pathway in HER3-
depleted cells upon 5-FU or Ox treatment, as indicated by 
the inhibition of AKT phosphorylation (Figure 1A and 1B, 
lower panels). The above results were confirmed by the 
use of a second specific siRNA to interference with HER3 
expression (Supplementary Figure S3). 
Figure 1: Depletion of HER3 expression induces apoptosis and sensitizes colon cancer cells to 5-FluoroUracil and 
Oxaliplatin. Cell viability of transiently transfected siscr and siHER3 HT29, Pt-1, and Pt-2 cells, treated or not with 5-FU (A) upper panel) 
and Ox (B) upper panel) for 48 hours, was evaluated by Trypan Blue exclusion. The percentage of cell death is presented as mean +/– standard 
deviation of three independent experiments. Total cell lysates from transiently transfected siscr and siHER3 HT29, Pt-1, and Pt-2 cells, 
treated or not with 5-FU (A, lower panel) and Ox (B, lower panel) were analyzed by immunoblot to evaluate the expression of HER3, total 
and p-AKT, total and p-ERK, and PARP. The anti-HSP70 antibody was used to validate equivalent amount of loaded proteins in each lane. 
The results are presented as mean +/– standard deviation of three independent experiments *p < 0.05, **p < 0.001, ***p < 0.0001.
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Chemotherapy-induced genotoxic stress often 
activates multiple signal transduction pathways such 
as MAPK, aberrantly activated in CRC patients [38], 
which has been associated with anti-apoptotic processes 
and chemo-resistance development [39]. It has been 
hypothesized that MAPK activation may provide cancer 
cells with survival advantage and assist malignant cells 
escaping from the drug-induced apoptotic challenge 
[40]. In such a perspective, we also evaluated the 
phosphorylation levels of MAPK and found that both 
5-FU and Ox treatments, alone or in combination with 
HER3 depletion induce the up-regulation of p-ERK in 
HT29 and in Pt-2 cells while the results it is not evident 
in Pt-1 cells (Figure 1A and 1B, lower panels, and 
Supplementary Figure S4). These results are in agreement 
with recent findings indicating that one of the mechanisms 
of resistance to therapies involves the activation of 
compensatory pathways to which tumor cells become 
addicted [41–42].
Total and phospho-HER3 expression correlate 
with disease-free survival
To validate our in vitro data we analyzed, by 
immunohistochemistry (IHC), the expression level of 
total- and phospho-HER3 in specimens derived from 
patients surgically treated at the Regina Elena National 
Cancer Institute between 2000 and 2013. We correlated 
the expression of both isoforms with the Disease-Free 
Survival (DFS). To this end, we randomly selected 185 
CRC patients with a median follow-up of 66 months 
(95% CI 61.8–71.5), including 135 colon and 50 rectal 
carcinomas that were retrospectively evaluated for DFS. 
As summarized in Table 1, 21 patients (11%) 
were T1-2, 122 (66%) T3 and 42 (23%) T4. Eighty-six 
(46%) patients were lymph node negative and 99 (54%) 
were node positive. Furthermore, 153 (83%) CRC were 
graded, using the Bloom and Richardson scoring system, 
as well/moderate differentiated (G1-G2), and 32 (17%) as 
poorly differentiated (G3). Pathological staging identified 
73 (39%) and 68 (37%) tumors at stages I–II and III 
respectively and 44 (24%) at stage IV. Tumors were 
staged according to the Unione Internationale Contre le 
Cancer tumor-node-metastasis system criteria (TNM Ed.7, 
2009). The study was reviewed and approved by the ethics 
committee of the Regina Elena National Cancer Institute.
One hundred and sixty eight (91%) and 105 (57%) 
CRC patients were found positive for HER3 and pHER3, 
respectively (Table 1, Figure 2A a, b). Figure 2A c shows 
the IHC analysis of a representative HER3 negative 
specimen. In Supplementary Figure S5 are reported 
the levels of total- and pHER3 expression scored semi-
quantitatively based on staining intensity (0, 1+, 2+, 
and 3+) whose percent of distribution, using the IRS 
described in statistical analysis section, is reported in 
Figure 2B–2D. 
When the entire series of 185 cases with complete 
follow-up data was analyzed by unadjusted Kaplan-Meier 
curves, low HER3 was able to identify subgroups of 
patients at lower risk of relapse (P = 0.048) (Figure 2B). 
By contrast, in the entire series of 185 patients stage 
I–IV, pHER3 expression had no discernible effect on DFS 
(P = 0.12) (Figure 2C). However, when we excluded from 
this analysis the patients at stage IV, which is linked to 
many additional modifications that induce a profound 
change in the biology of tumors, in the remaining 141 
patients, stage I–III, high pHER3 expression predicted 
significantly shorter DFS (p = 0.02) (Figure 2D). 
Univariate and multivariate analyses (Cox model) 
further confirmed these data, identifying high expression 
(score > 10) of pHER3 as a significant predictor of worse 
DFS in the 141 patients described above (HR 1.94, 
CI 1.06 to 3.58, p = 0.03 and HR 1.85, CI 1.0 to 3.42, 
P = 0.05) (Figure 2E). Interestingly, we found that in a 
subset of lower pHER3 patients (stage I-IV), the higher 
pHER3 expression in patients with stage I-III predicted 
a significant shorter DFS (p = 0.0009) (Supplementary 
Figure S6A, and S6B).
Inhibition of HER3 activity by patritumab 
induces growth arrest in patient-derived colon 
cancer cells Pt-1 and Pt-2
Patritumab is the first fully human monoclonal 
immunoglobulin G1 (IgG1) antibody directed against 
HER3 binds specifically to the extra-cellular domain of 
HER3 [22]. In order to verify the growth inhibition ability 
previously showed by this antibody in multiple tumor cell 
lines, we analyzed its effect in patient-derived colon cancer 
cell lines. In order to render the patritumab efficient in our 
cell lines, that do not express a constitutively active form of 
HER3 tyrosine kinase receptor, we treated all the cell lines 
with HRG-β1 to induce HER3 phosphorylation, making 
the receptor targetable for the antibody. We found that the 
treatment of HT29, Pt-1 and Pt-2 cell lines with patritumab, 
under stimulation with HRG-β1, induces a significant 
inhibition of cell proliferation (Figure 3A, 3B and 3C, upper 
left panels). A more detailed analysis confirmed that the 
treatment with patritumab does not induce apoptosis; indeed 
the analysis of total cell lysates from samples collected after 
4, 24, 48, 72 and 96 hours of incubation with patritumab, 
revealed that the total levels of PARP remain unaffected 
(Figure 3A, 3B and 3C, left lower panels). We then checked 
for the cell cycle distribution of cells collected at the time 
points of the same experiment and we found that patritumab 
treatment inhibits cell cycle progression inducing a block of 
the cells at the G1 phase of the cell cycle. The accumulation 
of patritumab-treated cells at the G1 phase reached the 
maximum level between 72 and 96 hours post-treatment in 
the cell lines analyzed (Figure 3A, 3B and 3C, right panels). 
These data allow us to confirm that patritumab induces 
growth arrest also in patient-derived colon cancer cells. 
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Patritumab inhibits PI3K survival pathway 
and induces the phosphorylation of ERK as a 
compensatory mechanism
It has been shown that patritumab treatment 
induces rapid internalization and degradation of HER3 
receptor [22]. Further evidence showed that this antibody 
inhibits the PI3K survival pathway in lung cancer and 
head and neck cell lines [43]. To analyze the molecular 
perturbations induced by patritumab treatment in the 
patient-derived colon cancer cell lines Pt-1, Pt-2, Pt-3 and 
in the colon cancer cell line HT29, we incubated all cell 
lines with patritumab under stimulation with HRG-β1. The 
stimulation induces a rapid activation of HER3 and AKT, 
measured as phosphorylation levels, in all cell lines up to 
24 h of treatment (Figure 4A–4D, left panels). By contrast, 
patritumab treatment abrogates the HRG-β1-induced 
HER3 phosphorylation and, as expected, induces rapid 
internalization and degradation of the receptor that results 
in the abrogation of AKT phosphorylation (Figure 4A–4D, 
right panels) compared to control cells (Figure 4A–4D, 
left panels). 
Interestingly, we also found that patritumab 
treatment results in a significant up-regulation of total 
HER2 in all cell lines analyzed (Figure 4A–4D right 
panels vs left panels). This data was further confirmed by 
FACS analysis (Supplementary Figure S7A). By contrast, 
patritumab treatment does not modulate significantly 
EGFR in HT29 and in Pt-1 cells, while we observed a 
significant increase of the receptor in Pt-2 and Pt-3 cells 
(Figure 4C and 4D). This result is in agreement with 
recent observations indicating that cancer cells respond 
to targeted inhibitors by adapting their signaling circuitry, 
often in terms of activation of compensatory signaling 
mechanisms [42]. Indeed, the increase of HER2 and 
EGFR receptors induced by patritumab treatment resulted 
in the activation of MAPK pathway in all treated cells 
compared to control cells (Figure 4A–4D, right vs left 
panels). Densitometry analysis of HER2 and EGFR are 
reported in Supplementary Figure S7B. The involvement 
Table 1: Bio-pathological characteristics of 185 colorectal carcinomas 
Characteristics N° %
Number of patients       185
Tumor size
 T1-2   21 11
 T3 122 66
 T4   42 23
Lymph node status
 Negative 86 46
 Positive 99 54
Grading
 G1-2 153 83
 G3   32  17
Stage
 I–II 73 39
 III 68 37
 IV 44 24
HER3 status
 0 17  9
 1+ 56 30
 2+ 98 53
 3+ 14  8
pHER3 status
 0 80 43
 1+   2   1
 2+ 85 46
 3+ 18 10
185 CRC cases were classified for tumor size, lymph node status, grading, and stage, total and phospho-HER3 status.
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of both receptors in the compensatory mechanism 
promoted by patritumab treatment was confirmed by 
blocking the signaling of EGFR and HER2 by erlotinib 
and trastuzumab, respectively. Indeed, in the presence of 
patritumab, the inhibition of both receptors does not allow 
the activation of MAPK (Supplementary Figure S8). 
Figure 2: Total and p-HER3 expression correlates with disease-free survival in CRC specimens. (A) Representative CRC 
cases showing: (a) total HER3 positivity, (b) phospho-HER3 positivity on the consequential section, (c) negative HER3 expression. Scale 
bar 100 µm. Kaplan-Meier estimates DFS for HER3 (B) and pHER3 status (C) in 185 stage I–IV CRC patients. (D) Estimates of DFS for 
pHER3 status in the I–III stage CRC patients. P-values were calculated using the long-rank test. DFS = Disease-free Survival. L = Low 
expression, H = High expression. (E) Univariate and multivariate analyses performed in the 141 stage I–III patients. 
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Figure 3: Patritumab administration inhibits cell proliferation and induces growth arrest in the G1 phase of the cell 
cycle. 5 × 104 cells of HT29 (A), Pt-1 (B), and Pt-2 (C) cell lines were seeded into six-well plates. HRG-β1-stimulated cells, patritumab-
treated or untreated, were collected at the indicated times and counted in 0.2% trypan blue solution (left, upper panels). The cells incubated 
with 10 ng/ml HRG-β1 and 10 μg/ml patritumab antibody for the indicated times were lysed and analyzed by immunoblot to evaluate the 
expression of PARP. Anti-HSP70 antibody was used to validate equivalent amount of loaded proteins in each lane (left, lower panels). The 
same cells were stained in PBS containing propidium iodide and RNase-A overnight at 4°C. The DNA content of the cells was measured 
by fluorescence-activated cell sorting (FACS) (right panels). A total number of 1 × 104 cells for each sample were acquired. The results are 
presented as mean +/– standard deviation. *p < 0.05; **p < 0.001; ***p < 0.0001 compared to control.
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The MEK-inhibitor trametinib activates the 
HER3-dependent PI3K survival pathway
Since the treatment of colon cancer cell lines with 
patritumab down-regulates PI3K signaling but results 
in the activation of MAPK pathway as a compensatory 
mechanism, we decided to test the effect induced by the 
MEK-inhibitor trametinib. It has been previously described 
that the MEK inhibitor trametinib rapidly induces hyper-
phosphorylation of HER3 tyrosine kinase receptor in 
a panel of melanoma cell lines harboring a variety of 
BRAFV600E/K mutations [35]. The authors showed that 
up-regulation of phospho-HER3 is due to an autocrine 
loop involving increased transcription and production of 
neuregulin by melanoma cells. HER3 has been involved in 
intrinsic resistance to MEK inhibition also in KRAS mutant 
lung and colon cancers [36] and it has been found that 
MEK inhibition by selumatenib results in MYC-dependent 
transcriptional up-regulation of HER3, which is responsible 
for intrinsic drug resistance. Thus, we treated our Pt-1, Pt-2, 
Figure 4: Patritumab administration inhibits the PI3K survival pathway and activates the MAPK proliferation 
pathway. Total cell lysates from HT29 (A), Pt-1 (B), Pt-2 (C), and Pt-3 (D) cells, incubated with 10 ng/ml HRG-β1 and 10 μg/ml 
patritumab antibody for the indicated times, were analyzed by immunoblot to evaluate the expression of total and P-HER3, HER2, EGFR, 
total and p-AKT, total and p-ERK. The anti-HSP70 antibody was used to validate equivalent amount of loaded proteins in each lane.
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Pt-3, and HT29 cells with trametinib, in order to evaluate 
the responsiveness of the cells to the drug. As expected, 
trametinib treatment induced a rapid inhibition of ERK 
phosphorylation in all cell lines, which was evident 1 
hour following exposure to the drug and was maintained 
up to 48 hours (Figure 5). Interestingly, we also found 
that trametinib treatment determines a rapid and strong 
induction of HER3 phosphorylation, resulting in AKT 
activation, between 24 and 48 hours of treatment in all cell 
lines (Figure 5). The densitometry analysis of p-Akt and 
p-MAPK reported in Supplementary Figure S9 confirms the 
above results. This last result is in agreement with previous 
data showing that the MEK inhibitor semulatenib induces 
HER3 transcriptional up-regulation and phosphorylation 
in vivo in KRAS mutant lung and colon cancers [36]. 
Our data confirm that MEK inhibition by trametinib 
induces the HER3-dependent activation of PI3K survival 
pathway independently of the status of BRAF and KRAS 
oncogenes, and suggest that the compensatory mechanism 
activated by the MEK inhibitor could be independent from 
the genetic background of the cells.
Dual targeting of HER3 and MEK impairs colon 
cancer cell viability
According to previous data, we targeted both PI3K 
and MAPK pathways by treating colon cancer cells with 
patritumab in combination with trametinib. As expected, 
upon stimulation with HRG-β1, the single treatment with 
patritumab inhibits PI3K but activates MAPK pathway; on 
the contrary, trametinib abrogates ERK but activates HER3 
receptor (Figure 6A, upper panels). The treatment with both 
inhibitors resulted in abrogation of both pathways (Figure 
6A, upper panels); indeed Pt-1, Pt-2 and Pt-3 patient-derived 
colon cancer cells treated with the combined therapy show 
the inhibition of HER3, AKT, and ERK phosphorylation 
indicating that the compensatory activation of the two 
pathways induced by the single drug results in a strong 
response when they are administrated in combination. 
The dual inhibition by patritumab and trametinib induces 
cell death by apoptosis in Pt-3 cells, reaching a 40% of 
cell death upon 72 h (Figure 6B, lower panel). The same 
treatment does not induce cell death in Pt-1, Pt-2, and 
HT29, as suggested by PARP cleavage (Figure 6B, lower 
panels), but the viability of these cells is severely impaired, 
suggesting that the dual therapy induces a block of cell cycle 
progression. These results were confirmed by TUNEL assay 
showing that patritumab and trametinib treatments alone or 
the combination of both induces apoptosis only in Pt-3 cells 
(Supplemnary Figure S10A and S10B).
DISCUSSION
The development of resistance to therapy remains 
an unresolved issue in the treatment of CRC. The number 
of proteins and signaling pathways implicated in the 
mechanisms of drug resistance has increased through the 
last years, and it has been well established that somatic 
alterations in key components of these pathways can 
function as driver mutations during oncogenesis. A number 
of these cancer drivers, as well as other core proteins in the 
signaling pathways, have received much attention from the 
pharmaceutical industry as ‘‘drugable’’ targets for tumor 
therapy. Moreover, it is clear that tumors can contain a 
high degree of molecular heterogeneity [44], thus drug 
resistance can arise through therapy-induced selection of a 
resistant minor subpopulation of cells present in the tumor. 
Therefore it is increasingly clear the need to hit multiple 
target pathways to overcome acquired resistance. 
Among various alterations, up-regulated RTK 
signaling, due to mutation or amplification of the 
receptors, contributes to a variety of human malignancies, 
with members of the ErbB family being prominent cancer 
drivers. In these tumors the RAF/MEK/ERK and PI3K/
AKT/mTOR effector pathways are all activated [45].
Our data demonstrate that the expression and 
activity of HER3 correlate with lower DFS in a cohort 
of 185 specimens of colorectal cancer. We also show that 
HER3 is responsible, at least in part, for the acquired 
resistance of patient-derived CRC cells to 5-FU and Ox 
drugs. Indeed, the interference with HER3 expression 
induces cell death and sensitizes cancer cells to 
chemotherapy. Interestingly, patritumab treatment induces 
the up-regulation of HER2 and EGFR, which in turn 
activate MAPK pathway suggesting that a mechanism of 
signaling redundancy is induced by patritumab. A similar 
response has been reported in HER2-expressing breast 
cancer cells. In this case, inhibition of PI3K or AKT has 
been found to promote the expression of HER3 causing 
increased HER2/HER3 signaling and compensatory 
activation of the ERK cascade [46]. Other reports suggest 
that HER3 signaling and sustained PI3K/AKT activation 
are induced upon HER2 and EGFR-targeted therapy, and 
that patritumab can overcome the resistance induced by 
heregulin [47–49]. 
The ERK cascade is an important effector pathway 
that is upregulated in a high percentage of human tumors 
[50]. ERK signaling is driven by oncogenic RAS and 
RTK proteins, as well as by mutational activated BRAF 
proteins. BRAF and KRAS mutations are present in 
approximately 5–15% and 50% of cases, respectively 
[51–53]. The V600E BRAF mutation clearly functions as 
a driver mutation in colorectal cancer. However, unlike 
BRAF-mutated melanoma, single-agent BRAF inhibition 
has been an ineffective strategy in BRAF-mutated 
colorectal cancer. 
The differential sensitivity to BRAF inhibition 
displayed by BRAF-mutated melanoma and colorectal 
cancers may be partly explained by the EGFR protein. 
A key observation is that the vast majority of colorectal 
cancer expresses EGFR and the inhibition of BRAF 
triggers the activation of EGFR. The combined EGFR 
Oncotarget10www.impactjournals.com/oncotarget
Figure 5: Trametinib administration induces the HER3-dependent activation of PI3K pathway. Total cell lysates from 
HT29, Pt-1, Pt-2, and Pt-3 cells incubated with 10 ng/ml HRG-β1 or treated with 5 nM trametinib, for the indicated times, were analyzed 
by immunoblot to evaluate the expression of total and p-HER3, total and p-AKT, total and p-ERK. The anti-HSP70 antibody was used to 
validate equivalent amount of loaded proteins in each lane.
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and BRAF inhibition decreases cell proliferation and 
triggers apoptosis of BRAF-mutated colorectal cancer 
cell lines and xenografts [54]. On the contrary, melanomas 
do not express EGFR but forced expression of EGFR in 
melanoma cells leads to resistance to vemurafenib [55]. 
These preclinical observations led to the current clinical 
trials combining inhibitors of BRAF and EGFR. On 
the other hands, both mutations in KRAS and BRAF 
have been clearly demonstrated to predict resistance to 
EGFR-directed therapy in colorectal cancer [56–57]. A 
further difference between BRAF-mutated melanoma 
and colorectal cancer is that BRAF-mutated colorectal 
cancer cells possess higher levels of PI3K activation 
than BRAF-mutated melanoma cells, and that resistance 
to vemurafenib could be overcome by combining 
vemurafenib with PI3K inhibitors [58–60].
We show here that the MEK-inhibitor trametinib 
activates HER3-dependent PI3K pathway independently 
of the mutation status of KRAS and BRAF. Indeed we 
observed the same mechanism in three patient-derived 
colon cancer cell lines carrying BRAFV600E (Pt-1), 
KRASG13 (Pt-3) and wt BRAF and KRAS (Pt-2). 
Our results are in agreement with previous study 
demonstrating that in response to MEK inhibition 
colon cancer shows up-regulation of RTKs [36, 60]. 
Furthermore, HER3 up-regulation as a consequence of 
MEK inhibitor was observed in BRAF mutant thyroid 
carcinomas and melanomas [61], whereas trametinib 
was shown to induce hyper-phosphorylation of HER3 in 
BRAFV600E/K melanoma [35], and selumetinib-induced 
resistance in KRAS mutant lung and colon cancer is due to 
the transcriptional induction of HER3 [36]. In agreement, 
our results demonstrated that trametinib causes a strong 
suppression of MEK-ERK signaling in CRC, whereas 
AKT signaling was even increased in the presence of the 
inhibitor. Dual inhibition of MEK and HER3, obtained 
by combining trametinib and patritumab, determined 
the complete inhibition of both ERK and AKT signaling 
pathways resulting in a severely impaired viability of CRC 
cells. 
Figure 6: Dual targeting of HER3 and MEK impairs viability of colon cancer cells. (A) Total cell lysates from HT29, Pt-1, 
Pt-2, and Pt-3 cells incubated with 10 ng/ml HRG-β1, 5 nM trametinib, 10 μg/ml patritumab antibody, or a combination of trametinib and 
patritumab antibody, for 24 hours, were analyzed by immunoblot to evaluate the expression of total and p-HER3, total and p-AKT, total 
and p-ERK. The anti-HSP70 antibody was used to validate equivalent amount of loaded proteins in each lane. (B) Cell viability of HT29, 
Pt-1, Pt-2 and Pt-3 cells treated with 10 ng/ml HRG-β1, 5 nM trametinib, 10 μg/ml patritumab antibody, or a combination of trametinib and 
patritumab antibody for 72 hours, was evaluated by Crystal Violet assay. The results are presented as mean +/– standard deviation of three 
independent experiments. **p < 0.001; ***p < 0.0001 combined treatment compared to control and to trametinib alone.
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Our finding could have important implications, 
leading us to suggest a specific therapeutic strategy for a 
subgroup of HER3-overexpressing CRCs. 
MATERIALS AND METHODS
Cell lines 
The colon cancer cell line HT29, carrying mutant 
BRAFV600E and PIK3CAP449T, was obtained from 
the American Type Culture Collection (ATCC) and 
maintained in DMEM medium supplemented with 10% 
FCS, 1% penicillin/streptomycin and 1% glutamine 
(Invitrogen, Milan, Italy). The patient-derived colon 
cancer cell lines: Pt-1 carrying mutant BRAFV600E and 
PIK3CAP449T; Pt-2 carrying wild type (wt) BRAF and 
mutant PIK3CAH1047R; Pt-3 carrying mutant KRAS 
G13 and mutant PIK3CAE542K were kindly provided 
by Istituto Superiore di Sanità (ISS) and maintained 
in DMEM medium supplemented with 10% FCS, 1% 
penicillin/streptomycin and 1% glutamine (Invitrogen, 
Milan, Italy). All the cell lines, with the exception of Pt-3 
cells, carry mutant p53.
Treatments
To induce the phosphorylation of HER3, the cells 
were stimulated with HRG-β1 (R&D Systems, Milan, 
Italy), at the concentration of 10 ng/ml for the indicated 
times. The anti-HER3 antibody patritumab was kindly 
provided from Daiichi Sankyo (Tokyo, Japan) was used 
at the concentration of 10 μg/ml. The chemotherapeutic 
drugs 5-FU and Ox were purchased from Teva Italia 
(Assago, Mi) and used at the concentration of 50 and 
20 μM, respectively. The anti-MEK inhibitor trametinib 
(GSK-1120212) (Selleckchem, Milan, Italy) was used at 
the concentration of 5 nM. The treatment were performed 
at the indicated times.
Antibodies 
Rabbit anti-phospho-ser473 (#9271) and total-
AKT (#9272), anti-phospho- (#9101L) and total-ERK 
1/2 (#9102), anti-PARP (#9542), anti-phospho- (#2247) 
and total-HER2 (#2165), anti-phospho- (#3777) and 
total-EGFR (#4267), and anti-phospho-HER3 (#4791) 
antibodies were purchased from Cell Signaling (Milan, 
IT). Rabbit anti-HER3 (sc-285) antibody was purchased 
from Santa Cruz Biotechnology (Milan, IT), and mouse 
anti-HSP70 (N27F34) antibody was purchased from 
Stressgen (Milan, IT). These antibodies were used in 
Western Blot experiments. Rabbit anti-HER2 (#554299), 
purchased from BD Biosciences (Milan, IT), was used in 
immunofluorescence (FACS) analysis experiments. Total 
and phospho-HER3 (#12708 and #4791, respectively) 
were purchased from Cell Signaling and used for 
immunohistochemistry (IHC).
FITC and Peroxidase-conjugated secondary 
antibodies anti-IgGs were purchased from Cappel and/or 
BioRad (Milan, IT). 
Western blot analysis
To analyze phospho and total-HER3, phospho and 
total-HER2, phospho and total-EGFR, phospho- and Total-
ERK 1/2, PARP, and HSP70 proteins expression, the cells 
were lysed with RIPA buffer [50 mM Tris (pH 8), 150 mM 
NaCl, 1% Nonidet P40, 0,1% deoxycholate, 0,1% SDS, 
1 mM PMSF, 5 mM Na3VO4, 50 mM protease inhibitors 
(SIGMA-Aldrich, Milan, IT)] for 30 minutes at 4°C. Total 
cell lysates were clarified by centrifugation at 14,000 rpm 
for 30 minutes at 4°C. To analyze P-AKT the cells were 
washed three times with cold PBS, lysed with NP40 buffer 
[(1% Nonidet P40, 10% glycerol, 137 mM NaCl, 20 mM 
Tris HCl (pH 7,4), 50 mM NaF, 1 mM PMSF, 5 mM 
Na3VO4, 50 mM protease inhibitors (SIGMA-Aldrich, 
Milan, IT)] and incubated on ice for 20 minutes. Total 
cell lysates were clarified by centrifugation at 14,000 rpm 
for 30 minutes 4°C. Aliquots of cell extracts containing 
equivalent amount of proteins were treated at 65°C for 
5 minutes, resolved by SDS-polyacrilamide gradient gel 
electrophoresis 8–16% (SDS-PAGE), and transferred to 
nitrocellulose. The horseradish peroxidase-conjugated 
goat anti-mouse or ant-rabbit were used as secondary 
antibodies. Signals were detected by LuminataTM 
Classico Western HRP substrate (Millipore). Same amount 
of total protein from three independent experiments 
were pooled and analyzed. Total loaded proteins were 
normalized by anti-HSP70.
Flow cytometry analysis
The expression level of HER2 in HT29, Pt-1, and 
Pt-2 cells was detected by flow cytometry analysis of 
stained cells. In brief, cells harvested using citrate saline 
buffer (0.134 M KCl, 0.015 M Na citrate) were washed 
twice with cold PBS containing 0.002% EDTA and 10 mM 
NaN3 (washing buffer). Samples of 1 × 10
6 cells, treated 
as indicated, were incubated for 1 h at 4°C with saturating 
concentrations of anti-HER2 diluted in PBS containing 
0.5% bovine serum albumin (BSA). The cells were then 
washed three times with washing buffer (PBS containing 
0.5% BSA) and incubated for 1 h at 4°C with 50 µl of 
FITC-conjugated secondary antibodies [F(ab')2 diluted 1:20 
in PBS/BSA]. After three washes, the cells were suspended 
in 1 ml of washing buffer. Cell suspensions were analyzed 
on a FACSCalibur flow cytometer (Becton-Dickinson, San 
Josè, CA, USA) equipped with a 488 nm argon laser. A total 
number of 1 × 104 cells for each sample was acquired. The 
Cell-Quest software was used to analyze data. 
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RNA interference
To inactivate HER3 expression (siHER3), cells 
were transiently transfected with Lipofectamine 2000 
(Invitrogen, Milan, Italy) following the manufacturer 
procedures with either two different HER3 anti-sense 
double strand siRNA: 
1) 5ʹ-GCUCUACGAGAGGUGUGAGTT-3ʹ
5ʹ-CUCACACCUCUCGUAGAGCTT-3ʹ
2) 5ʹ-GAGCGACUAGACAUCAAGCTT-3ʹ
5ʹ-GCUUGAUGUCUAGUCGCUCTT-3ʹ
or a scrambled anti-sense double strand siRNA 
(siscr) 
5ʹ-GCGCGCAACUCUACCUCUATT-3ʹ
5ʹ-UAGAGGUAGAGUUGCGCGCTT-3ʹ.
The oligonucleotides were synthesized by 
Oligoengine Inc. (Seattle, WA).
Cell proliferation and cell death
HT29, Pt-1, and Pt-2 cells (5 × 104) were plated onto 
six-well plates. After an overnight of serum starvation, the 
cells were incubated with 10 ng/ml HRG-β1 (ctr cells) 
and 10 μg/ml patritumab antibody for the indicated times. 
Every 24 h cells were collected and counted in 0.2% 
trypan blue solution, whereas medium changes were 
performed for the remaining samples. Each assay was 
repeated at least three times.
HT29, Pt-1, Pt-2, and Pt-3 cells (5 × 105) were plated 
onto 60 mm dishes. The day after, the cells were transiently 
transfected with si-scr or si-HER3. After 24 h the cells 
were treated with 50 mM 5-FU or 20 mM Ox alone or in 
combination with si-HER3 for 48 hrs. The viability of the 
cells was evaluated by trypan blue exclusion or by TUNEL 
assay. For the treatment with patritumab and trametinib 
treatment alone or in combination, 4 × 104 of HT29, Pt-1, 
Pt-2 and Pt-3 cells were plated in triplicate in 24-well 
plate. 24 hours later cells were incubated with patritumab 
antibody at a final concentration of 10 μg/ml, trametinib at a 
final concentration of 5 nM, or a combination of both drugs. 
After 72 hours, cells were fixed in 4% formaldeyde for 
15 minutes, then the cells were incubated with a solution 
of 0, 1% crystal violet in 10% ethanol. After 40 minutes the 
crystal violet solution was removed and cells washed with 
water and let to air-dry. Thereafter, crystals were solubilized 
in 10% acetic acid and absorbance was measured at 570 nm 
on a μQuant plate reader (BIO-TEK instruments inc, 
Milan, Italy). Each assay was repeated at least three times. 
The TUNEL assay was performed by In Situ Cell Death 
Detection Kit, Fluorescein (Roche, MI, Italy).
Cell cycle analysis
After an overnight of serum starvation, HT29, Pt-1 
and Pt-2 cell lines were incubated with 10 ng/ml HRG-β1 
and 10 μg/ml patritumab antibody for the indicated times.
The cells were harvested by treatment with 0.25% 
trypsin, fixed with ice-cold 70% ethanol solution, and 
stained in PBS containing propidium iodide and RNase 
A overnight at 4°C. The DNA content of the cells was 
measured by fluorescence-activated cellsorting (FACS). 
Cell suspensions were analyzed on a FACSCalibur flow 
cytometer (Becton-Dickinson, San Josè, CA, USA) 
equipped with a 488 nm argon laser, after addition of 
5 µl of a 1 mg/ml solution of propidium iodide to exclude 
non-viable cells. A total number of 1 × 104 cells for each 
sample were acquired. The Cell-Quest software was used 
to analyze data.
Tissue microarray construction
All colorectal cancers included in the study were 
histopathologically re-evaluated on haematoxylin and 
eosin stained slides and representative areas were marked 
prior to tissue microarray (TMA) construction.
Two core cylinders (1 mm diameter) were taken 
from CRC and deposited into two separate recipient 
paraffin blocks using a specific arraying device (Alphelys, 
Euroclone, Milan, Italy). In cases where informative 
results on TMA were absent due to missing tissue, no 
tumor tissue, we re-analyzed the correspondent routine 
tissue section. Two-mµ sections of the resulting microarray 
block were made and used for immunohistochemical 
(IHC) analysis after transferring them to SuperFrost Plus 
slides (Menzel-Gläser, Braunschweig, Germany). 
Immunohistochemistry
Immunohistochemical staining on TMA was 
performed using the following primary antibodies: 
anti-HER3 rabbit monoclonal antibody (D22C5) (Cell 
Signaling, Sial, Rome, Italy) and phospho-HER3 rabbit 
monoclonal antibody (Tyr1289-21D3) (Cell Signaling) in 
an automated immunostainer (Bond-III, Leica, Italy). A 
pH 8 buffer was used for the two antibodies as antigen 
retrieval according to the manufacturer’s protocol. 
Images were obtained at 20x magnification by using a 
light microscope (DM2000 LED, Leica) equipped with 
software able to capture images (Leica).
Statistical methods
Levels of HER3 and pHER3 expression were 
scored semi-quantitatively based on staining intensity and 
distribution percentage using the immune-reactive score 
(IRS, staining intensity × percentage of positive cells). 
IRS was classified as low intensity and high intensity. The 
analysis by means of maximally selected log-rank statistics 
were performed to find optimal cut-offs for IRS capable 
of splitting patients into groups with different outcomes 
probabilities. The association between variables was tested 
by the Pearson Chi-Square test or Fisher’s Exact test, 
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when appropriate. Hazard ratios (HR) and 95% confidence 
intervals (95% CI) were estimated for each variable using 
the Cox univariate model; a multivariate Cox proportional 
hazard model was developed using stepwise regression 
(forward selection, enter/remove limits p = 0.10 and 
p = 0.15 respectively), in order to identify independent 
predictors of outcomes; potential interactions between 
significant variables were taken into account when 
developing the multivariate model. Survival curves were 
calculated by the Kaplan-Meier product limit method from 
the date of the surgery until relapse/progression or death. 
The log-rank and Tarone-Ware tests were used to assess 
differences between subgroups. Significance was defined 
at the p ≤ 0.05 level. 
Student T test was used to analyze cell lines 
proliferation, death data and cell cycle expressed as mean 
percentage. Student T test was also used to analyze the 
densitometry. Differences were considered statistically 
significant when P ≤ 0.05 (*P < 0.05, **P < 0.001, ***P < 
0.0001). All analyses were performed using SPSS® (21.0), 
R® (2.6.1) statistical programs (Chicago, Illinois). 
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